Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Bookman

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
Gastroenterology|September 1, 1979
Characteristics of isolated intestinal mucosal lymphoid cells in inflammatory bowel diseaseM A Bookman, D M Bull
Hematology/Oncology Clinics of North America|August 1, 1992
Biologic and immunologic therapy of ovarian cancerM A Bookman, J S Berek
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Factoring outcomes in ovarian cancerM A Bookman, R F Ozols
Seminars in Oncology|June 11, 1991
The immunobiology and immunotherapy of ovarian cancerM A Bookman, R C Bast
Cancer Treatment Reviews|June 1, 1986
Concomitant illness in patients treated for Hodgkin's diseaseM A Bookman, D L Longo
Seminars in Oncology Nursing|November 1, 1993
Future directions for paclitaxel (TAXOL) in the treatment of ovarian cancerM A Bookman, R F Ozols
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 1987
Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clonesM A Bookman, R Swerdlow, L A Matis
Molecular and Cellular Biology|October 1, 1989
Alterations in tyrosine protein phosphorylation induced by antibody-mediated cross-linking of the CD4 receptor of T lymphocytesA Veillette, J B Bolen, M A Bookman
Journal of the National Cancer Institute. Monographs|January 1, 1990
Late complications of Hodgkin's disease managementR C Young, M A Bookman, D L Longo
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 17, 2003
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5M A Bookman, B E Greer, R F Ozols
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Gastroenterology|September 1, 1979
Characteristics of isolated intestinal mucosal lymphoid cells in inflammatory bowel diseaseM A Bookman, D M Bull
Hematology/Oncology Clinics of North America|August 1, 1992
Biologic and immunologic therapy of ovarian cancerM A Bookman, J S Berek
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Factoring outcomes in ovarian cancerM A Bookman, R F Ozols
Seminars in Oncology|June 11, 1991
The immunobiology and immunotherapy of ovarian cancerM A Bookman, R C Bast
Cancer Treatment Reviews|June 1, 1986
Concomitant illness in patients treated for Hodgkin's diseaseM A Bookman, D L Longo
Seminars in Oncology Nursing|November 1, 1993
Future directions for paclitaxel (TAXOL) in the treatment of ovarian cancerM A Bookman, R F Ozols
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 1987
Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clonesM A Bookman, R Swerdlow, L A Matis
Molecular and Cellular Biology|October 1, 1989
Alterations in tyrosine protein phosphorylation induced by antibody-mediated cross-linking of the CD4 receptor of T lymphocytesA Veillette, J B Bolen, M A Bookman
Journal of the National Cancer Institute. Monographs|January 1, 1990
Late complications of Hodgkin's disease managementR C Young, M A Bookman, D L Longo
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 17, 2003
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5M A Bookman, B E Greer, R F Ozols
Pageof 8